Search Videos and More
News
Chain Reaction: The Belzutifan Journey
Countless medical innovations are born in academic laboratories.
News
Potential Targeted Therapy for Pediatric Brain Cancer Identified by Dana-Farber/Boston Children's Team
An international team of clinical collaborators, led by physician scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma.
Video
Kidney Cancer Conference Highlights from ASCO GU 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates, focused on clear cell renal cell carcinoma (ccRCC), you need to know from GU ASCO 2025.
Video
Bladder Cancer Conference Highlights from ASCO GU 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from GU ASCO 2025. Highlights in this video include more details on the CheckMate274, NIAGRA, and INDUCT trials.
Video
Prostate Cancer Conference Highlights from ASCO GU 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from GU ASCO 2025. This video highlights updates in mCRPC and oligometastatic prostate cancer trials.
Video
Wenxin (Vincent) Xu, MD presents a potential biomarker (KIM-1)
Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.
Video
Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan
Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma.
News
Early Cancer Detection Studies for High-Risk People
A blood test can now detect the presence of 50 different cancers — most of which do not have any other means of screening.
News
Dana-Farber Researchers Present Findings at 2025 ASCO Genitourinary Cancers Symposium
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif.
News
A Year of Advances in Genitourinary Cancer
Dana-Farber’s genitourinary cancer team is devoted to research that will advance patient care and improve patient’s lives. Recently, that research — all of it years in the making — has paid off with major achievements.
News
Study of Inherited Prostate Cancer Genetics in Africa Highlights Importance of Research
The genetic landscape of prostate cancer susceptibility in Africa is, like the continent itself, a picture of sweeping diversity, the largest study of the phenomenon concludes.
News
Prostate Cancer Vaccines: What’s the Latest?
Like all vaccines, prostate cancer vaccines work by stimulating the body’s immune system. Unlike vaccines for the flu, COVID-19 and other infections, which protect against disease, prostate cancer vaccines are a form of treatment.?